Results 191 to 200 of about 134,721 (265)

Modulating Th17/Treg Balance in Alzheimer's Disease: Therapeutic Insights from Natural Compounds and Immunometabolism. [PDF]

Brain Sci
Tang S, Fu G, Yu W, Zhou M, Chen T, Song Z, Cheng S, Li P.   +7 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Analysis of the predictive value of Th17/Treg cells and cytokines for the risk of infection after kidney transplantation. [PDF]

Front Immunol
Li W, Guo J, Yang H, Wang B.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Genetically predicted serum Pimelylcarnitine mediates the association between CD39+ secreting Treg cells and intervertebral disc degeneration. [PDF]

Medicine (Baltimore)
Li N, Shen C, Huang Z, Shao Z, Wu J, Hua D, Wang L.   +6 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

From Development to Aging: Dynamic Roles of the Thymic Medulla in T Cell Biology. [PDF]

Immunol Rev
Michalaki C, Sharjeel M, Cowan JE.
europepmc   +1 more source

Pt‐TiO2 mesoporous nanosystem co‐delivering phlorezin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation

BMEMat, EarlyView.
Abstract Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO2 nanoparticles for the co‐delivery of Phlorezin, presenting a novel approach for HCC treatment through sonodynamic ...
Kairui Liu, Bo Zhang, Yue Wan, Zhiru Yang, Abdusami Abdurahman, Mengxin He, Shengtao Hu, Yi Zhang, Xiaoke Li, Jin Chang, Jun Kang, Liren Liu, Wanghua Liu, Shao Li   +13 more
wiley   +1 more source

Boosting "Treg-ulation": a good way to treat chronic GVHD? [PDF]

Blood Adv
Boiko JR, Carpenter PA.
europepmc   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

BMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning, Yunhan Sun, Mingyang Li, Shilu Liu, Fangjie Yi, Hongfei Wang, Ruibing Bai, Dongdong Liu, Fen Zhao, Guiqiang Zhang, Xiao Fu   +10 more
wiley   +1 more source